Magnosco GmbH

Magnosco GmbH, founded in 2014, is a MedTec Company based in the technology park Berlin-Adlershof. We offer a non-invasive method supporting (early) detection of malignant melanoma based on laser technology. CEO Inga Bergen and COO Thomas Diepold lead the team of scientist and technical experts. Magnosco cooperates with Charité Berlin, University Hospital of Tübingen and the University Hospital of Heidelberg, hospital operator Vivantes and LTB Lasertechnik Berlin regarding the development and certification as a medical device. More and more people know that if skin lesions are changing a doctor’s expertise is very important to detect skin cancer early on. Especially dangerous is the “black skin cancer” (malignant melanoma). The number of cases increases continuously. If detected early the prognosis for a patient is very good. Now, a well-researched non-invasive method supporting (early) detection of malignant melanoma is ready for the doctors’ offices: with laser beam, so called dermatofluoroscopy. How does it work? Melanin is a skin pigment which works as a natural protective mechanism against sun. When a skin cell changes abnormally, the structure of melanin changes too. Scientist managed to light up melanin with an infrared laser. Fluoresces the melanin stronger in the colour range of green or blue the cell is normal. Strong fluorescence in the red colour range indicates a malignant cell degeneration. The scientists call this the “universal fingerprint” of malignant melanoma, which is clearly identifiable on a molecular level with this method.